Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677845 | 0.89 | FPR2 (0.58) | LMNAATMNPSR1MAPK1FPR2 | |
| SCHEMBL4475766 | 0.89 | FPR2 (0.58) | LMNAATMNPSR1MAPK1FPR2 | |
| SCHEMBL1405960 | 0.89 | FPR2 (0.58) | LMNAATMNPSR1MAPK1FPR2 | |
| SCHEMBL11614286 | 0.88 | LMNA (0.63) | LMNAATMNPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL11615245 | 0.88 | NPSR1 (0.64) | LMNAATMNPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL20334984 | 0.88 | NPSR1 (0.64) | LMNAATMNPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL20335020 | 0.87 | NPSR1 (0.74) | LMNAATMNPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL6380632 | 0.87 | NPSR1 (0.74) | LMNAATMNPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL11617093 | 0.87 | LMNA (0.79) | LMNAATMNPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL14903139 | 0.86 | NPSR1 (0.73) | LMNAATMNPSR1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
| US-4093444-A | Hydantoin derivatives and methods for regulating plant-growth | PEPRO, SOCIETE POUR LE DEVELOPPEMENT ET LA VENTE DE SPECIALITES CHIMIQUES (FR) | 1978-06-06 | — | — | US | disclosed |
| US-3990883-A | N-(1-carboxy-3-methylthio)propyl urea derivatives and compositions having plant-growth regulating properties | PEPRO, SOCIETE POUR LE DEVELOPEMENT ET AL VENTE DE SPECIALITIES CHIMIQUES (FR) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | F11, F12, F2 | LMNA 436/4885ATM 3493/4885NPSR1 1781/4885 |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | CNR2, CNR1, HCAR2 | LMNA 445/4885ATM 4489/4885NPSR1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.